MFLRC | License & Regulatory Consultants

For years, the slowest and most expensive part of bringing a biosimilar to Canada was the comparative clinical efficacy trial, the large head-to-head study that tried to show the biosimilar performed like its reference biologic in patients. Health Canada has now revised its biosimilar guidance so that, in most cases, this trial is no longer required. That single change reshapes the development timeline, the budget and the risk profile for every company planning a biosimilar in Canada.

It does not, however, lower the bar for approval. It moves the weight of evidence earlier, onto analytical characterization and clinical pharmacology, and it leaves several obligations fully intact. This article explains what changed, when it changed, and the question that now matters most for sponsors: if the Phase 3 trial is gone, what must you still prove to convince Health Canada that your product is a biosimilar?

Executive Summary

Health Canada revised its guidance on information and submission requirements for biosimilar biologic drugs. The draft was released on 10 June 2025, the consultation closed on 8 September 2025, and the revised guidance followed in 2026. In most cases, a comparative clinical efficacy and safety trial is no longer required. Similarity must instead be established primarily through comprehensive comparative analytical studies, supported by a comparative pharmacokinetic study, pharmacodynamic data where a relevant endpoint exists, and comparative immunogenicity and safety data. Extrapolation across the reference product's indications is available where high similarity and equivalent dosing are demonstrated, without a separate justification for each indication. What does not change is the need for a complete quality dossier, a sound comparability exercise, a pharmacovigilance plan and the possibility that Health Canada will ask for more clinical data where residual uncertainty remains. Sponsors should confirm the current version of the guidance before finalizing a development plan and, where useful, request a pre-submission meeting.

What Changed: Health Canada and the Comparative Efficacy Trial

What it is: Health Canada has revised the clinical expectations for biosimilars so that a comparative clinical efficacy and safety trial is not required in most cases. The revised guidance states that similarity is best demonstrated through comparative analytical and functional studies, which are generally more sensitive than clinical outcome studies for detecting differences between a biosimilar and its reference biologic. A comparative clinical efficacy trial is now reserved for the limited situations where residual uncertainty cannot be resolved by analytical and pharmacology data.

Why it matters: the comparative efficacy trial was often the single largest cost and the longest line on a biosimilar development plan. Removing it as a default can shorten timelines and reduce cost, which changes the commercial case for entering the Canadian market and can affect the timing of patent litigation under the Patented Medicines (Notice of Compliance) Regulations. It also shifts risk forward: if your analytical and pharmacology package is weak, there is no large clinical study later to compensate for it.

What to do: rebuild your development plan around a strong analytical comparability package and a well-designed comparative pharmacokinetic study. Decide early whether a pharmacodynamic endpoint is available, and plan immunogenicity assessment from the start. Where the science is finely balanced, a pre-submission interaction with Health Canada is the most reliable way to confirm that your reduced clinical package will be accepted.

Milestone	Date	What it means
Draft revised guidance released	10 June 2025	Health Canada proposed removing the general comparative efficacy trial requirement
Consultation closed	8 September 2025	Stakeholder comment period ended
Revised guidance adopted	2026	The no comparative efficacy trial approach was finalized; confirm the posted version and effective date before relying on it

Why Analytical Similarity Is Now the Foundation

What it is: a biosimilar is approved on the totality of the evidence, and under the revised approach the foundation of that evidence is the comparative analytical exercise. This means a comprehensive, side-by-side characterization of the biosimilar and its reference biologic: primary and higher-order structure, post-translational modifications such as glycosylation, charge and size variants, purity and impurity profiles, and a panel of functional or biological assays that probe the mechanisms relevant to the product's action. Stability data complete the picture.

Why it matters and what to do: if the Phase 3 trial is no longer the safety net, the analytical package must carry the argument. A narrow characterization that leaves a quality attribute unexplained is now a direct risk to approval, not a gap that a clinical study might paper over. Use orthogonal methods, justify your analytical similarity ranges against multiple reference lots, and tie each functional assay to a mechanism of action. This is where quality by design and a disciplined comparability protocol earn their value.

The Clinical Package That Remains: PK, PD and Immunogenicity

What it is: removing the efficacy trial does not remove clinical data. The clinical programme now centres on a comparative pharmacokinetic study designed to show equivalence in how the body handles the biosimilar and the reference product. A comparative pharmacodynamic assessment is included where a clinically relevant pharmacodynamic endpoint exists. Comparative safety and immunogenicity data are collected, typically through the same clinical pharmacology study, because immunogenicity is a product-specific risk that analytical testing alone cannot fully predict.

Why it matters and what to do: the comparative pharmacokinetic study is now the pivotal clinical element, so its design, population, dose and equivalence margins must be defensible before you start. Immunogenicity planning should define the assay strategy, sampling schedule and clinical consequences of an anti-drug antibody response. Because these are clinical trials, they must be conducted to current Good Clinical Practice. Our guide to the ICH E6(R3) readiness plan for Canada sets out the quality-by-design and risk-proportionate expectations that now govern trial conduct.

Evidence element	Still required?	Purpose
Comparative analytical and functional studies	Yes, as the foundation	Establish high structural and functional similarity
Comparative pharmacokinetic study	Yes, pivotal clinical element	Demonstrate equivalent exposure
Comparative pharmacodynamic data	Where a relevant endpoint exists	Support similarity with a clinically meaningful marker
Comparative immunogenicity and safety	Yes	Address a product-specific risk analytics cannot fully predict
Comparative clinical efficacy trial	Only in exceptional cases	Resolve residual uncertainty that cannot be addressed otherwise

Indication Extrapolation Without a Trial for Each Indication

What it is: extrapolation lets a biosimilar be authorized for indications of the reference product that were not directly studied in the biosimilar programme. Under the revised approach, where high similarity and equivalent dosing are demonstrated, the reference product's authorized indications can be granted without a separate, detailed scientific justification for each one. The justification flows from the overall similarity, the mechanism of action and the clinical pharmacology, rather than from indication-by-indication clinical data.

Why it matters and what to do: extrapolation is one of the main efficiencies of the biosimilar pathway, and the revised guidance makes it more straightforward where the science supports it. Confirm that the mechanism of action and the relevant receptors or targets are the same across the indications you seek, that the dosing is equivalent, and that any indication with a distinct safety or immunogenicity concern is addressed. Do not assume automatic extrapolation where an indication involves a different mechanism or a different patient population.

A Biosimilar Is Not a Generic: CMC and Comparability Still Apply

What it is: a reduced clinical package can make a biosimilar sound like a generic small-molecule drug. It is not. A biosimilar is a biologic manufactured in living systems, and it needs a full chemistry, manufacturing and controls dossier for its own distinct process: cell line, upstream and downstream processing, formulation, control strategy and stability. The comparability exercise against the reference product sits on top of that complete quality file, not in place of it.

Why it matters and what to do: treating a biosimilar submission like a generic is a fast route to a clarification request or a notice of deficiency. Build the quality dossier to the standard expected of any biologic, apply ICH quality guidelines for development and comparability, and make sure your control strategy manages the quality attributes that matter most to similarity. If your process changes during development, a comparability assessment of your own product, before and after the change, is part of the story.

Post-Market: Pharmacovigilance, Immunogenicity Monitoring and Naming

What it is: approval is not the end of the evidence. Biosimilars carry pharmacovigilance obligations, including a risk management plan, ongoing safety reporting and attention to immunogenicity signals in real-world use. Clear product identification, so that an adverse event can be traced to the specific product a patient received, is part of responsible post-market safety for biologics.

Why it matters and what to do: a lighter pre-market clinical package raises the importance of post-market vigilance, because some rare safety and immunogenicity signals only appear at scale. Build your pharmacovigilance system to detect and investigate them, and make sure your mandatory reporting is sound. Our overview of Vanessa's Law and mandatory reporting explains the Canadian post-market reporting and recall obligations that apply, and lifecycle tools such as terms and conditions under agile licensing can shape what Health Canada expects after authorization.

When Health Canada Can Still Ask for Clinical Data

What it is: the removal of the comparative efficacy trial is a default, not a guarantee. Where residual uncertainty about biosimilarity remains after the analytical and pharmacology package, Health Canada can still request additional clinical data, including a comparative efficacy study in exceptional cases. The reviewer judges the totality of the evidence, and a weak link anywhere in the package can trigger a request for more.

Why it matters and what to do: plan for the possibility that a reviewer will ask for more. Health Canada can seek new information during a review, as our explainer on the Access Consortium work-sharing pilot describes, so a development plan that assumes a frictionless review is fragile. Where a faster route fits your product, pathways such as the foreign reliance order and conditional approval under notice of compliance with conditions are worth assessing early, and disciplined responses to any notice of deficiency, handled within the time limits on NOD and NON extensions, keep a submission on track.

What Sponsors Must Still Prove: A Compliance Checklist

Use this list to confirm your biosimilar submission is built on the evidence Health Canada still expects, even without a comparative efficacy trial.

Comprehensive comparative analytical package covering structure, higher-order structure, post-translational modifications, charge and size variants, purity and functional activity.
Analytical similarity ranges justified against multiple reference product lots, using orthogonal methods.
Comparative pharmacokinetic study designed for equivalence, with defensible population, dose and margins.
Comparative pharmacodynamic data included where a clinically relevant endpoint exists.
Comparative immunogenicity and safety data, with a defined anti-drug antibody assay strategy and sampling plan.
Extrapolation rationale confirming shared mechanism of action, equivalent dosing and any indication-specific safety considerations.
Complete chemistry, manufacturing and controls dossier for the biosimilar's own process, with a comparability exercise for any in-development process change.
Clinical studies conducted to current Good Clinical Practice under ICH E6(R3).
Risk management plan and pharmacovigilance system ready for post-market immunogenicity and safety monitoring.
Current version and effective date of the Health Canada biosimilar guidance confirmed, with a pre-submission meeting where the package is finely balanced.

Common Mistakes

Treating a biosimilar like a generic. It needs a full biologic quality dossier and a comparability exercise, not an abbreviated file.
Under-investing in the analytical package. With no default efficacy trial, a weak characterization has nothing to fall back on.
Treating extrapolation as automatic. It depends on shared mechanism, equivalent dosing and indication-specific safety, not on the reference label alone.
Leaving immunogenicity planning late. The assay strategy and clinical interpretation should be defined before the clinical pharmacology study starts.
Assuming the review will be frictionless. Health Canada can request additional clinical data where residual uncertainty remains.
Relying on secondary summaries of the guidance. Confirm the current version and effective date on the Health Canada page before you plan.

Frequently Asked Questions

Are Phase 3 trials still required for biosimilars in Canada?

In most cases, no. Health Canada's revised biosimilar guidance states that a comparative clinical efficacy and safety trial is not required in most cases. Similarity is established primarily through comparative analytical and functional studies, a comparative pharmacokinetic study, pharmacodynamic data where relevant, and comparative immunogenicity and safety data. A comparative efficacy trial is reserved for exceptional cases where residual uncertainty cannot be resolved.

When did Health Canada make this change?

The draft revised guidance was released on 10 June 2025, and the consultation closed on 8 September 2025. The revised guidance was adopted in 2026. Because Health Canada updates its posted guidance from time to time, sponsors should confirm the current version number and effective date on the Health Canada guidance page before relying on it.

What does a biosimilar sponsor still have to submit?

A complete chemistry, manufacturing and controls dossier for the biosimilar's own process, a comprehensive comparative analytical and functional characterization against the reference product, a comparative pharmacokinetic study, pharmacodynamic data where a relevant endpoint exists, comparative immunogenicity and safety data, an extrapolation rationale, and a pharmacovigilance and risk management plan.

Can a biosimilar still be approved for indications it was not studied in?

Yes, through extrapolation. Where high similarity and equivalent dosing are demonstrated, the reference product's authorized indications can be granted without a separate clinical study for each. The rationale rests on shared mechanism of action and clinical pharmacology, and any indication with a distinct safety or immunogenicity concern must still be addressed.

Is a biosimilar the same as a generic drug?

No. A generic is a chemically identical copy of a small-molecule drug. A biosimilar is a highly similar version of a biologic made in living systems, where small differences are expected. That is why a biosimilar needs a full biologic quality dossier, a comparability exercise and comparative clinical pharmacology, even though a comparative efficacy trial is usually not required.

Could Health Canada still ask for a clinical efficacy trial?

Yes. The removal of the comparative efficacy trial is a default based on the totality of the evidence. Where residual uncertainty about biosimilarity remains after the analytical and pharmacology package, Health Canada can request additional clinical data, including a comparative efficacy study in exceptional cases.

How MFLRC Can Help

MFLRC helps biologic and biosimilar sponsors turn the revised guidance into a defensible development plan. We run a dossier gap assessment against the current requirements, advise on analytical comparability strategy and the design of the comparative pharmacokinetic study, build the quality management and pharmacovigilance systems a biologic needs, and prepare for pre-submission interactions and review questions. Explore our regulatory affairs, licensing and import and export services and our audit and gap assessment services. If a reduced clinical package is central to your business case, confirm the plan before you commit the budget.

Planning a biosimilar for the Canadian market? Book an MFLRC regulatory strategy session and we will map your evidence package against the current Health Canada requirements and flag the gaps before they become review questions.

Conclusion

Removing the default comparative efficacy trial is a meaningful efficiency for biosimilar sponsors in Canada, but it is not a shortcut. The evidentiary weight has moved earlier, onto analytical characterization and clinical pharmacology, and the obligations around quality, immunogenicity, extrapolation and post-market safety remain fully in force. Sponsors who build a strong analytical package, design a defensible pharmacokinetic study, plan immunogenicity from the start and confirm the current guidance with Health Canada will capture the benefit of the change. Those who treat a biosimilar like a generic will meet it as a clarification request instead. Verify every detail against the current Health Canada guidance before you finalize a plan.

Biosimilars in Canada Without Phase 3 Trials: What Sponsors Must Still Prove